Cargando…
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers representing approximately 20% of all lung cancers, including small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). The frequency appears to be approximately 3% for LCNEC. Diagnosis of LCNEC requires...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503246/ https://www.ncbi.nlm.nih.gov/pubmed/26039012 http://dx.doi.org/10.1097/JTO.0000000000000589 |
_version_ | 1782381283482009600 |
---|---|
author | Fasano, Morena Della Corte, Carminia Maria Papaccio, Federica Ciardiello, Fortunato Morgillo, Floriana |
author_facet | Fasano, Morena Della Corte, Carminia Maria Papaccio, Federica Ciardiello, Fortunato Morgillo, Floriana |
author_sort | Fasano, Morena |
collection | PubMed |
description | Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers representing approximately 20% of all lung cancers, including small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). The frequency appears to be approximately 3% for LCNEC. Diagnosis of LCNEC requires attention to neuroendocrine features by light microscopy and confirmation by immunohistochemical staining for neuroendocrine markers. Both SCLC and pulmonary LCNEC are high-grade and poor-prognosis tumors, with higher incidence in males and smokers and peripheral localization. LCNEC is very rare, and the precise diagnosis on small specimens is very difficult, so we have still too few data to define a standard of treatment for pulmonary LCNECs. Data of literature, most based on retrospective analysis, indicated a poor 5-year overall survival, with a high incidence of recurrence after surgery, even in stage I disease. Primary surgery should be the first option in all operable patients because there is no validate therapeutic approach for LCNEC due to lack of clinical trials in this setting. Neoadjuvant platinum-based regimens remain only an option for potentially resectable tumors. In advanced stages, SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival (from 8 to 16 months in different case series). New agents are under clinical investigation to improve LCNEC patients’ outcome. We reviewed all data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease. |
format | Online Article Text |
id | pubmed-4503246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-45032462015-08-05 Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy Fasano, Morena Della Corte, Carminia Maria Papaccio, Federica Ciardiello, Fortunato Morgillo, Floriana J Thorac Oncol State of the Art: Concise Review Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers representing approximately 20% of all lung cancers, including small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). The frequency appears to be approximately 3% for LCNEC. Diagnosis of LCNEC requires attention to neuroendocrine features by light microscopy and confirmation by immunohistochemical staining for neuroendocrine markers. Both SCLC and pulmonary LCNEC are high-grade and poor-prognosis tumors, with higher incidence in males and smokers and peripheral localization. LCNEC is very rare, and the precise diagnosis on small specimens is very difficult, so we have still too few data to define a standard of treatment for pulmonary LCNECs. Data of literature, most based on retrospective analysis, indicated a poor 5-year overall survival, with a high incidence of recurrence after surgery, even in stage I disease. Primary surgery should be the first option in all operable patients because there is no validate therapeutic approach for LCNEC due to lack of clinical trials in this setting. Neoadjuvant platinum-based regimens remain only an option for potentially resectable tumors. In advanced stages, SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival (from 8 to 16 months in different case series). New agents are under clinical investigation to improve LCNEC patients’ outcome. We reviewed all data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease. Lippincott Williams & Wilkins 2015-08 2015-07-23 /pmc/articles/PMC4503246/ /pubmed/26039012 http://dx.doi.org/10.1097/JTO.0000000000000589 Text en Copyright © 2015 by the International Association for the Study of Lung Cancer This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | State of the Art: Concise Review Fasano, Morena Della Corte, Carminia Maria Papaccio, Federica Ciardiello, Fortunato Morgillo, Floriana Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title_full | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title_fullStr | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title_full_unstemmed | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title_short | Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy |
title_sort | pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy |
topic | State of the Art: Concise Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503246/ https://www.ncbi.nlm.nih.gov/pubmed/26039012 http://dx.doi.org/10.1097/JTO.0000000000000589 |
work_keys_str_mv | AT fasanomorena pulmonarylargecellneuroendocrinecarcinomafromepidemiologytotherapy AT dellacortecarminiamaria pulmonarylargecellneuroendocrinecarcinomafromepidemiologytotherapy AT papacciofederica pulmonarylargecellneuroendocrinecarcinomafromepidemiologytotherapy AT ciardiellofortunato pulmonarylargecellneuroendocrinecarcinomafromepidemiologytotherapy AT morgillofloriana pulmonarylargecellneuroendocrinecarcinomafromepidemiologytotherapy |